Glenmark Pharmaceuticals Ltd; a pharmaceutical company headquartered in Mumbai, India, plans to set up a new manufacturing facility in the United States. The company plans to set up the manufacturing facility at Monroe Corporate Center, North Carolina. The facility will be spread over 100,000 square feet (an approximate 15-acre plot). The company will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topicals over a five-year period.

The company expects to start manufacturing activity by the end of the current financial year 2014–2015. This facility is dedicated only for the US market and is Glenmark's first manufacturing facility in North America. The company has 14 manufacturing plants in four countries: India, Brazil, Argentina, and Czech Republic.

Glenmark, which operates in North America through its subsidiary Glenmark Generics Inc.,  has a generics business with a portfolio of more than 90 products authorized for distribution in the US in niche segments, such as dermatology, hormones, controlled substances, oncology, and modified-release products. The company has nearly 70 abbreviated new drug applications pending approval with the US Food and Drug Administration, according to the company.

Source: Glenmark Pharmaceuticals